Abstract
A recent meta-analysis published in EClinicalMedicine examined the effectiveness of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), on cardiovascular (CV) outcomes [1]. Mixed EPA/DHA formulations were indicated to have moderate certainty in reducing CV mortality and outcomes. Greater relative reductions in incident CV events were observed with EPA alone trials. The authors conclude that EPA and DHA have inherently different physico-chemical properties that influence CV risk reduction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
